Vice President, Early Discovery Chemistry
Revolution Medicines
Vice President, Early Discovery Chemistry
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
The Vice President, Early Discovery Chemistry will report to the Senior Vice President of Medicinal Chemistry and Screening Platform Technologies and serve as the scientific and organizational leader for Revolution Medicines' Early Discovery Chemistry organization. The role will lead multidisciplinary teams spanning Early Discovery Chemistry, Analytical Chemistry, library sciences, and enabling discovery technologies to drive the identification of novel chemical matter for Revolution Medicines' oncology pipeline.
This executive will define and execute the strategy for discovering high-value chemical matter against challenging targets by integrating innovative chemistry, computational design, AI/ML, automation, and modern screening technologies. The organization will expand accessible chemical space, accelerating hit identification, and delivering differentiated chemical matter into Medicinal Chemistry for lead optimization.
The successful candidate will establish Early Discovery Chemistry as a center of scientific excellence that continuously advances technologies, capabilities, and workflows to improve the speed, quality, and probability of success of drug discovery across the Revolution Medicines portfolio.
Key responsibilities include driving innovation and advancing screening and synthesis technologies, building capabilities that expand diversity of the chemical space and accelerate the identification of high-value starting points and tools for drug discovery. The VP will foster close collaboration across biology, computational sciences, and downstream medicinal chemistry teams to ensure seamless progression from early discovery into lead optimization and contribute to advancing transformative science by demonstrating:
Vision, strategy, leadership: Collaborate with Research leadership to develop a long-term strategy for portfolio expansion through discovery of inhibitors of frontier oncology targets. Partner with biology and digital drug discovery to harness data analytics at all stages of discovery, and particularly. Provide vision, leadership and drive cross-functional alignment to support a dynamic portfolio of discovery and development stage projects.
Innovation: Provide scientific leadership for innovation across early discovery and medicinal chemistry, leveraging advances in AI/ML, data-informed approaches to accelerate DMTA cycles, computational design, data analysis, automation, innovative synthesis and screening approaches, and data science to accelerate discovery and expand access to novel chemical space. Foster a culture of creativity, scientific excellence.
Management excellence: Manage a high-performing group with multiple functions. Sustain productivity through strategic hiring, mentoring, and support for individual career growth. Be accountable for an annual budget.
Cross-functional collaboration: Position the Early Discovery Chemistry function as a bridge across Research, enabling bench-to-bedside insights. Partner with Medicinal Chemisry, Structural and Molecular Sciences, Digital Drug Discovery, Systems Biology, and Translational Research to identify molecular determinants of response, resistance, and target vulnerability and to inform discovery priorities.
Required Skills, Experience, and Education:
Ph.D. in Organic Chemistry, Medicinal Chemistry, or related discipline.
15+ years of industrial drug discovery experience with significant leadership responsibility in Early Discovery or Medicinal Chemistry.
Demonstrated success leading programs from target concept through hit identification and into lead optimization.
Hit identification; Library design and chemical diversity; Fragment-based drug discovery; Screening technologies; Computationally enabled molecular design.
Building and leading multidisciplinary scientific organizations.
Strong strategic leadership experience including organizational design, budgeting, hiring, and talent development.
Outstanding communication skills with demonstrated ability to influence senior leadership and cross-functional teams.
Ability to work in a high-energy, fast-paced, rapidly evolving and scaling company, operating in a highly competitive field.
Demonstrated ability to build, lead, and foster a collaborative culture on interdisciplinary teams.
Preferred Skills:
Experience discovering drugs against challenging oncology targets.
Experience with covalent inhibitors, molecular glues, targeted protein degradation, or ADC payload discovery.
Experience leading external collaborations and technology partnerships.
Record of scientific publications, patents, and industry recognition.
Experience advancing multiple discovery programs from target identification through candidate nomination.
#LI-Onsite #LI-GL1
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Base Pay Salary Range 294000 - 367000 USD
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines